Literature DB >> 23949904

Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways.

Ya-Yin Chen1, Hsu-Feng Lu, Shu-Chun Hsu, Chao-Lin Kuo, Shu-Jen Chang, Jen-Jyh Lin, Ping-Ping Wu, Jia-You Liu, Ching-Hsiao Lee, Jing-Gung Chung, Jin-Biou Chang.   

Abstract

Metastasis plays an important role in mortality of cancer patients. Migration and invasion are the major characteristics of tumor metastasis. The induction of matrix metalloproteinases (MMPs) such as MMP-2 and -9 are particularly important for the invasiveness of various cancer cells. Bufalin, a class of toxic steroids, was purified from the skin glands of Bufo gargarizans or Bufo melanostictus; it is known to inhibit proliferation of human cancer cells. In this study, we investigated the antiinvasive mechanisms of bufalin in the human hepatocellular cancer cell line SK-Hep1. Bufalin significantly reduced serum-induced cell invasion and migration. Furthermore, bufalin markedly inhibited MMP-2 and -9 activity, mRNA expression and protein levels in SK-Hep1 cells. Bufalin attenuated phosphoinisitide-3-kinase (PI3K) and phosphorylation of AKT which was associated with reduced levels of nuclear factor kappa B (NF-κB). Bufalin also suppressed protein levels of FAK and Rho A, VEGF, MEKK3, MKK7, and uPA and it diminished NF-κB translocation. Based on these observations, we propose that bufalin is acts as an antiinvasive agent by inhibiting MMP-2 and -9 and involving PI3K/AKT and NF-κB pathways. Bufalin is a potential therapeutic agent that may have efficacy in preventing the invasion and metastasis of malignant liver tumors.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  NF-κB; SK-Hep1; bufalin; matrix metalloproteinase-2/-9; migration

Mesh:

Substances:

Year:  2013        PMID: 23949904     DOI: 10.1002/tox.21896

Source DB:  PubMed          Journal:  Environ Toxicol        ISSN: 1520-4081            Impact factor:   4.119


  25 in total

Review 1.  Molecular mechanisms underlying the antimetastatic activity of bufalin.

Authors:  Jie Wang; Yue Xia; Qingshong Zuo; Teng Chen
Journal:  Mol Clin Oncol       Date:  2018-03-21

2.  Tumor-Targeted Delivery of Bufalin-Loaded Modified Albumin-Polymer Hybrid for Enhanced Antitumor Therapy and Attenuated Hemolysis Toxicity and Cardiotoxicity.

Authors:  Ying Xu; Lei Tang; Peng Chen; Mei Chen; Miaomiao Zheng; Feng Shi; Yanchun Wang
Journal:  AAPS PharmSciTech       Date:  2021-04-20       Impact factor: 3.246

3.  Bufalin, a bioactive component of the Chinese medicine chansu, inhibits inflammation and invasion of human rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  Xiaofeng Rong; Weidong Ni; Yongguang Liu; Jun Wen; Chunyan Qian; Linke Sun; Jiajia Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

4.  Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer.

Authors:  Qiang Hu; Bo Liang; Ying Sun; Xiao-Ling Guo; Yi-Jie Bao; Dong-Hao Xie; Ming Zhou; You-Rong Duan; Pei-Hao Yin; Zhi-Hai Peng
Journal:  Int J Nanomedicine       Date:  2014-08-21

5.  Bufalin Induces Mitochondria-Dependent Apoptosis in Pancreatic and Oral Cancer Cells by Downregulating hTERT Expression via Activation of the JNK/p38 Pathway.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Chengguang Sui; Fandong Meng; Yan Li; Liye Fu; Tao Jiang; Yang Wang; Jia Su; Youhong Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2015-12-10       Impact factor: 2.629

6.  3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.

Authors:  Wen-Xue Li; Li-Ping Chen; Min-Ying Sun; Jun-Tao Li; Hua-Zhang Liu; Wei Zhu
Journal:  Oncotarget       Date:  2015-09-15

7.  Radiosynthesis and pharmacokinetics of [18F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice.

Authors:  Zhaoshuo Yang; Jianhua Liu; Qingqing Huang; Zhouji Zhang; Jiawei Zhang; Yanjia Pan; Yunke Yang; Dengfeng Cheng
Journal:  Onco Targets Ther       Date:  2017-01-11       Impact factor: 4.147

8.  Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.

Authors:  Bo Zhai; Fengli Hu; Haijiang Yan; Dali Zhao; Xin Jin; Taishi Fang; Shangha Pan; Xueying Sun; Lishan Xu
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

Review 9.  Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents.

Authors:  Ji Qi; C K Tan; Saeed M Hashimi; Abu Hasanat Md Zulfiker; David Good; Ming Q Wei
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-06       Impact factor: 2.629

10.  Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.

Authors:  Zhikui Liu; Changwei Dou; Bowen Yao; Meng Xu; Linglong Ding; Yufeng Wang; Yuli Jia; Qing Li; Hongyong Zhang; Kangsheng Tu; Tao Song; Qingguang Liu
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.